



**Universiteit  
Leiden**  
The Netherlands

**Alirocumab and cardiovascular outcomes in patients with previous myocardial infarction: prespecified subanalysis from ODYSSEY OUTCOMES**

Chiang, C.E.; Schwartz, G.G.; Elbez, Y.; Szarek, M.; Bhatt, D.L.; Bittner, V.A.; ... ; ODYSSEY OUTCOMES Investigators

**Citation**

Chiang, C. E., Schwartz, G. G., Elbez, Y., Szarek, M., Bhatt, D. L., Bittner, V. A., ... Steg, P. G. (2022). Alirocumab and cardiovascular outcomes in patients with previous myocardial infarction: prespecified subanalysis from ODYSSEY OUTCOMES. *Canadian Journal Of Cardiology*, 38(10), 1542-1549. doi:10.1016/j.cjca.2022.05.021

Version: Publisher's Version  
License: [Creative Commons CC BY-NC-ND 4.0 license](https://creativecommons.org/licenses/by-nc-nd/4.0/)  
Downloaded from: <https://hdl.handle.net/1887/3590619>

**Note:** To cite this publication please use the final published version (if applicable).



## Clinical Research

# Alirocumab and Cardiovascular Outcomes in Patients With Previous Myocardial Infarction: Prespecified Subanalysis From ODYSSEY OUTCOMES\*

Chern-En Chiang, MD, PhD,<sup>a</sup> Gregory G. Schwartz, MD, PhD,<sup>b</sup> Yedid Elbez, MSc,<sup>c</sup> Michael Szarek, PhD,<sup>d,e</sup> Deepak L. Bhatt, MD, MPH,<sup>f,g</sup> Vera A. Bittner, MD, MSPH,<sup>h</sup> Rafael Diaz, MD,<sup>i</sup> Andrejs Erglis, MD,<sup>j</sup> Shaun G. Goodman, MD, MSc,<sup>k,l</sup> Emil Hagström, MD, PhD,<sup>m</sup> J. Wouter Jukema, MD, PhD,<sup>n</sup> Evangelos Liberopoulos, MD,<sup>o</sup> Megan Loy, BAppSc,<sup>p</sup> Robert Porody, MD,<sup>q</sup> Harvey D. White, DSc,<sup>r</sup> Tabassome Simon, MD, PhD,<sup>s</sup> and Philippe Gabriel Steg, MD,<sup>t,u,v,w,x</sup> for the ODYSSEY OUTCOMES Investigators<sup>†</sup>

<sup>a</sup> General Clinical Research Center, Division of Cardiology, Taipei Veterans General Hospital and National Yang Ming Chiao Tung University, Taipei, Taiwan; <sup>b</sup> University of Colorado School of Medicine, Aurora, Colorado, USA; <sup>c</sup> Deepcover, Puteaux, France; <sup>d</sup> State University of New York, Downstate School of Public Health, Brooklyn, New York, USA; <sup>e</sup> CPC Clinical Research and Division of Cardiology, University of Colorado School of Medicine, Aurora, Colorado, USA; <sup>f</sup> Brigham and Women's Hospital Heart & Vascular Center, Boston, Massachusetts, USA; <sup>g</sup> Harvard Medical School, Boston, Massachusetts, USA; <sup>h</sup> Division of Cardiovascular Disease, University of Alabama at Birmingham, Birmingham, Alabama, USA; <sup>i</sup> Estudios Cardiológicos Latino América, Instituto Cardiovascular de Rosario, Rosario, Argentina; <sup>j</sup> Pauls Stradins Clinical University Hospital, University of Latvia, Riga, Latvia; <sup>k</sup> St. Michael's Hospital, University of Toronto, Toronto, Ontario, Canada; <sup>l</sup> Canadian VIGOUR Centre, University of Alberta, Edmonton, Alberta, Canada; <sup>m</sup> Department of Medical Sciences, and Uppsala Clinical Research Centre, Uppsala University, Uppsala, Sweden; <sup>n</sup> Department of Cardiology, Leiden University Medical Center, Leiden, The Netherlands; <sup>o</sup> Faculty of Medicine, School of Health Sciences, University of Ioannina, Ioannina, Greece; <sup>p</sup> Sanofi, Bridgewater Township, New Jersey, USA; <sup>q</sup> Regeneron Pharmaceuticals, Tarrytown, New York, USA; <sup>r</sup> Green Lane Cardiovascular Services, Auckland City Hospital, Auckland, New Zealand; <sup>s</sup> Sorbonne Université, Assistance Publique-Hôpitaux de Paris, Hôpital Saint Antoine, Paris, France; <sup>t</sup> Department of Cardiology, Université de Paris, Paris, France; <sup>u</sup> Assistance Publique-Hôpitaux de Paris, Hôpital Bichat, Paris, France; <sup>v</sup> FACT (French Alliance for Cardiovascular Trials), Paris, France; <sup>w</sup> INSERM U1148, Paris, France; <sup>x</sup> Imperial College, Royal Brompton Hospital, London, United Kingdom

*See editorial by Leung and Anderson, pages 1550-1552 of this issue.*

### ABSTRACT

**Background:** After acute coronary syndrome (ACS), patients with a previous myocardial infarction (MI) may be at particularly high risk for major adverse cardiovascular events (MACE) and death. We studied the effects of the PCSK9 inhibitor alirocumab in patients with recent

Among patients hospitalized with acute coronary syndrome (ACS), the event is not the first for 18% to 22%.<sup>1-3</sup> Patients with previous myocardial infarction (MI) have higher subsequent events than those with stable coronary disease or patients with multiple risk factors.<sup>4</sup> The risk of recurrent events in patients who have experienced previous MI continues for several years without

### RÉSUMÉ

**Contexte :** Après un syndrome coronarien aigu (SCA), les patients ayant déjà subi un infarctus du myocarde (IM) peuvent présenter un risque particulièrement élevé d'événements cardiovasculaires indésirables majeurs (ECIM) et de décès. Nous avons évalué les effets

evidence of decreasing risk.<sup>5</sup> The heightened risk of recurrent events is largely attributable to frequent coexistence of nonobstructive lesion with high-risk characteristics.<sup>6</sup> Therefore, management of patients with recurrent ACS after previous MI presents a particular challenge for clinicians: What additional medical therapies may help to prevent these recurrent events?

Received for publication May 4, 2022. Accepted May 22, 2022.

\*A limited set of these data was presented at the Annual Scientific Session of the American College of Cardiology, held in May 2021.

†A complete list of the ODYSSEY OUTCOMES committee members, investigators, and contributors is provided in Supplemental Appendix S1.

Corresponding author: Dr Chern-En Chiang, General Clinical Research Center and Division of Cardiology, Taipei Veterans General Hospital, 201, Section 2, Shih-Pai Road, Taipei 112, Taiwan. Tel.: +886-2-2875-7774; fax: +886-2-2872-3191.

E-mail: [cechiang@vghtpe.gov.tw](mailto:cechiang@vghtpe.gov.tw)

See page 1547 for disclosure information.

ACS according to previous history of MI.

**Methods:** The ODYSSEY OUTCOMES trial compared alirocumab with placebo, beginning 1 to 12 months after ACS with median 2.8-year follow-up. The primary MACE outcome comprised death from coronary heart disease, nonfatal MI, fatal or nonfatal ischemic stroke, and hospitalization for unstable angina. Of 18,924 patients, 3633 (19.2%) had previous MI.

**Results:** Patients with previous MI were older, more likely male, with more cardiovascular risk factors and previous events. With placebo, 4-year risks of MACE and death were higher among those with vs without previous MI (20.5% vs 8.9%,  $P < 0.001$ ; 7.4% vs 3.4%,  $P < 0.001$ , respectively). Alirocumab reduced the risk of events regardless of the presence or absence of a history of MI (MACE, adjusted hazard ratio [aHR] 0.90, 95% confidence interval [CI], 0.78-1.05 vs 0.82, 0.73-0.92;  $P_{\text{interaction}} = 0.34$ ; death, aHR 0.84; 95% CI, 0.64-1.08 vs 0.87, 0.72-1.05;  $P_{\text{interaction}} = 0.81$ ). Estimated absolute risk reductions with alirocumab were numerically greater with vs without previous MI (MACE, 1.91% vs 1.42%; death, 1.35% vs 0.41%).

**Conclusions:** A previous history of MI places patients with recent ACS at high risk for recurrent MACE and death. Alirocumab reduced the relative risks of these events consistently in patients with or without previous MI but with numerically greater absolute benefit in the former subgroup. (ODYSSEY OUTCOMES: NCT01663402)

Lipid lowering with high-intensity statin therapy is a cornerstone of management in ACS.<sup>1,2</sup> Proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors, added to statins, have the potential to lower atherogenic lipoproteins below levels achievable with statins and have been shown to improve clinical outcomes after ACS in patients with low-density lipoprotein cholesterol (LDL-C) above goal on optimized statin therapy.<sup>7</sup> In this prespecified analysis of the ODYSSEY OUTCOMES trial, we investigated the relative and absolute benefits of treatment with the PCSK9 inhibitor alirocumab in patients with ACS who had or did not have previous MI.

## Material and Methods

### Study population

ODYSSEY Outcomes (ClinicalTrials.gov: NCT01663402) was a randomized double-blind placebo-controlled trial that enrolled 18,924 patients  $\geq 40$  years of age who had been hospitalized with ACS (acute MI or unstable angina) 1 to 12 months before randomization.<sup>7,8</sup> The study conformed to the principles of the Declaration of Helsinki and was approved by the institutional review board at each site. All patients gave written informed consent to participate.

To be eligible, patients had to have LDL-C values  $\geq 70$  mg/dL (1.81 mmol/L) or non-high-density lipoprotein cholesterol (HDL-C) value  $\geq 100$  mg/dL (2.59 mmol/L), or

de l'alirocumab, un inhibiteur de la proprotéine convertase subtilisine/kexine de type 9 (PCSK9), chez les patients ayant récemment subi un SCA et présentant des antécédents d'IM.

**Méthodologie :** Lors de l'essai ODYSSEY OUTCOMES, le traitement par l'alirocumab, comparé à un placebo, a été instauré de 1 à 12 mois après un SCA, avec un suivi médian de 2,8 ans. Le principal paramètre d'évaluation des ECIM comprenait le décès lié à la coronaropathie, l'IM non fatal, l'accident vasculaire cérébral ischémique fatal ou non fatal et l'hospitalisation pour angine instable. Sur les 18 924 patients de l'étude, 3 633 (19,2 %) avaient déjà eu un IM.

**Résultats :** Les patients ayant des antécédents d'IM étaient plus âgés, étaient plus souvent de sexe masculin, et présentaient davantage de facteurs de risque cardiovasculaire et d'antécédents d'événements cardiovasculaires. Dans le groupe sous placebo, les risques d'ECIM et de décès à 4 ans étaient plus élevés chez les patients présentant des antécédents d'IM que chez ceux n'en présentant pas (20,5 % vs 8,9 %,  $p < 0,001$ ; 7,4 % vs 3,4 %,  $p < 0,001$ , respectivement). L'alirocumab a réduit le risque de survenue d'événements, peu importe la présence ou l'absence d'antécédents d'IM (ECIM : rapport des risques instantanés corrigé [RRIC] de 0,90; intervalle de confiance [IC] à 95 % : de 0,78 à 1,05 vs RRIC de 0,82; IC à 95 % : de 0,73 à 0,92;  $p_{\text{interaction}} = 0,34$ ; décès : RRIC de 0,84; IC à 95 % : de 0,64 à 1,08 vs RRIC de 0,87; IC à 95 % : de 0,72 à 1,05;  $p_{\text{interaction}} = 0,81$ ). Les réductions estimées du risque absolu avec l'alirocumab étaient numériquement supérieures chez les patients ayant des antécédents d'IM que chez ceux sans antécédents d'IM (ECIM : 1,91 % vs 1,42 %; décès : 1,35 % vs 0,41 %).

**Conclusions :** Des antécédents d'IM exposent les patients ayant récemment subi un SCA à un risque plus élevé de récurrence d'ECIM et de décès. L'alirocumab réduit le risque relatif de survenue de ces événements chez les patients avec ou sans antécédents d'IM, mais le bénéfice absolu est numériquement plus élevé chez les patients ayant des antécédents. (ODYSSEY OUTCOMES : NCT01663402)

apolipoprotein B value  $\geq 80$  mg/dL, measured after a minimum of 2 weeks on stable treatment with intensive LDL-C-lowering drugs (atorvastatin 40 to 80 mg daily, rosuvastatin 20 to 40 mg daily, or the maximum-tolerated dose of either statin, including no statin in the case of documented unacceptable side effects). Full inclusion and exclusion criteria have been published.<sup>8</sup>

Patients were randomly assigned (in a 1:1 ratio), stratified by country, to receive treatment with alirocumab 75 mg subcutaneously every 2 weeks or matching placebo. In the event of a persistent LDL-C value  $\geq 50$  mg/dL, the alirocumab dose was uptitrated to 150 mg. In patients who had 2 consecutive measurements of LDL-C  $< 25$  mg/dL, the alirocumab dose was reduced to 75 mg (for measurements made on the 150-mg dose), and safety was monitored by an independent physician blinded to treatment allocation. In the case of 2 consecutive measurements of LDL-C  $< 15$  mg/dL on alirocumab 75 mg, alirocumab was discontinued, with blinded substitution of placebo for the remainder of the trial. Occurrence of MI before the index ACS was a prespecified subgroup of interest, with the data collected at enrollment.<sup>8</sup>

### Trial outcomes

The primary composite outcome was a composite of major adverse cardiovascular events (MACE: death from coronary heart disease, nonfatal MI, fatal or nonfatal ischemic stroke, or unstable angina requiring hospitalization). Secondary

**Table 1. Baseline characteristics stratified by MI status at baseline**

Characteristics	Previous MI (n = 3633)	No previous MI (n = 15,291)	P value
Age, y	59.8 (9.3)	58.3 (9.3)	< 0.001
Female sex	756 (20.8)	4006 (26.2)	< 0.001
Medical history before index ACS			
Hypertension	2884 (79.4)	9365 (61.3)	< 0.001
Diabetes	1167 (32.1)	3478 (22.8)	< 0.001
Current tobacco smoker	849 (23.4)	3711 (24.3)	0.25
Family history of premature coronary artery disease	1543 (42.5)	5230 (34.2)	< 0.001
PCI	2,399 (66.0)	842 (5.5)	< 0.001
CABG	727 (20.0)	320 (2.1)	< 0.001
Stroke	180 (5.0)	431 (2.8)	< 0.001
Peripheral artery disease	265 (7.3)	494 (3.2)	< 0.001
Heart failure	970 (26.7)	1844 (12.1)	< 0.001
Body mass index, kg/m <sup>2</sup>	29.2 (4.9)	28.3 (4.9)	< 0.001
Renal function			
EGFR, mL/min per 1.73 m <sup>2</sup>	77.4 (19.7)	80.2 (19.1)	< 0.001
EGFR < 60 mL/min per 1.73 m <sup>2</sup>	635 (17.5)	1905 (12.5)	< 0.001
Index ACS			
ST-segment elevation MI	866 (23.8)	5670 (37.1)	< 0.001
Non-ST-segment elevation MI	2064 (56.8)	7111 (46.5)	< 0.001
Unstable angina	695 (19.1)	2484 (16.2)	< 0.001
PCI or CABG for index ACS	2308 (63.5)	11,368 (74.3)	< 0.001
Median time from index ACS to randomization, months	2.6 (1.7-4.2)	2.6 (1.7-4.4)	0.27
LDL-C, mg/dL	90.0 (75.7-110.4)	85.7 (72.6-102.7)	< 0.001
LDL-C ≥ 100 mg/dL	1305 (35.9)	4324 (28.3)	< 0.001
HDL-C, mg/dL	42.0 (35.9-49.8)	42.9 (36.7-50.2)	0.004
Non-HDL-C, mg/dL	121.2 (103.9-145.0)	113.5 (98.5-135.0)	< 0.001
Triglycerides, mg/dL	137.0 (98.0-193.0)	127.4 (92.9-179.6)	< 0.001
Lipoprotein(a), mg/dL	41.8 (45.4)	38.3 (42.8)	< 0.001
Apolipoprotein B, mg/dL	83.0 (72.0-98.0)	78.0 (68.0-92.0)	< 0.001
Apolipoprotein A, mg/dL	131.0 (118.0-147.0)	132.00 (118.0-147.0)	0.64
C-reactive protein, mg/dL	0.2 (0.1-0.4)	0.2 (0.1-0.4)	0.12
Hemoglobin A1c, %	5.9 (5.6-6.6)	5.8 (5.5-6.3)	< 0.001

Values are number (percentage), mean (standard deviation [SD]) or median (quartile 1 to quartile 3).

ACS, acute coronary syndrome; CABG, coronary artery bypass graft; EGFR, estimated glomerular filtration rate; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein-cholesterol; MI, myocardial infarction; PCI, percutaneous coronary intervention; SD, standard deviation.

outcomes included all-cause death.<sup>7</sup> All primary and secondary outcomes were adjudicated by physicians who were unaware of the trial-group assignments.

### Statistical analyses

Categorical variables were compared with  $\chi^2$  tests and continuous variables by Student's *t*-test. A Cox proportional hazards model was used to determine hazard ratios (HRs) and 95% confidence intervals (CIs) for MACE and death in patients with and without previous MI in the placebo group, adjusted for the following baseline variables: age ( $\geq 65$  years vs  $< 65$  years), sex, race, geographic region, diabetes mellitus, smoking; history of heart failure, ischemic stroke, and peripheral artery disease; intensive statin treatment; LDL-C and lipoprotein(a) concentrations; and systolic blood pressure. A Cox proportional hazards model was used to compare the treatment effect in the subgroups of patients with and without previous MI. Heterogeneity between patients with and without a previous MI was analyzed with a test for treatment-by-subgroup interaction. The Gail-Simon test was used to analyze the quantitative interaction for absolute risk reduction.<sup>9</sup> The cumulative incidence rates of MACE and death were estimated by the Kaplan-Meier method. *P* values were estimated by a log rank test over the previous MI status subgroups. The analysis was performed in SAS version 9.4 (IBM, Armonk, NY).

## Results

### Patient characteristics

Among 18,924 patients in the trial, 3633 (19.2%) had histories of MI before the qualifying ACS. The baseline characteristics of the patients are shown in [Table 1](#). Compared with patients without previous MI, those with a previous MI were older; more likely to be male, white; and to have more underlying cardiovascular conditions, previous cardiovascular events and procedures including stroke, peripheral artery disease, heart failure, impaired renal function, percutaneous coronary intervention, and coronary artery bypass graft surgery. In patients with previous MI, the qualifying ACS was more often non-ST elevation MI, and they had higher baseline levels of LDL-C, non-HDL-C, triglycerides, apolipoprotein B, lipoprotein(a), and hemoglobin A1c, but lower HDL-C. Other baseline characteristics are shown in [Supplemental Table S1](#). Findings were similar when patients with and without previous MI were compared in each randomization arm (alirocumab or placebo) ([Supplemental Table S2](#)).

### Risks of mace and death in the placebo group stratified by previous MI status at baseline

In the placebo group, the incidence of MACE (20.5% vs 8.9%; adjusted HR [aHR], 1.85; 95% CI, 1.62-2.11; *P* <

0.001), all-cause death (7.4% vs 3.4%; aHR, 1.56, 95% CI, 1.25-1.95;  $P < 0.001$ ), and other outcomes were higher among those with previous MI (Table 2). Exceptions were ischemic stroke and hospitalization for unstable angina, which were directionally congruent.

### Effect of alirocumab on MACE and death stratified by previous MI status at baseline

Figure 1 shows adjusted risk of outcomes for alirocumab vs placebo stratified according to previous MI status at baseline. In the overall study population, alirocumab reduced MACE by 15.0% (HR, 0.85; 95% CI, 0.78-0.93;  $P < 0.001$ ).<sup>7</sup> Among patients with previous MI, MACE occurred in 20.5% of patients in the placebo group vs 18.6% in the alirocumab group (aHR, 0.90; 95% CI, 0.78-1.05). Among patients without previous MI, MACE occurred in 8.8% of patients in the placebo group vs 7.4% in the alirocumab group (aHR, 0.82, 95% CI, 0.73-0.92;  $P_{\text{interaction}} = 0.34$ ). The estimated 4-year absolute risk reduction in MACE was numerically greater in patients with previous MI (1.91%; 95% CI, -0.67 to 4.49 vs 1.42%; 95% CI, 0.55-2.28; quantitative  $P_{\text{heterogeneity}} = 0.72$ ). Among patients with previous MI, 7.4% of patients in the placebo group died vs 6.0% in the alirocumab group (aHR 0.84; 95% CI, 0.64-1.08). Among patients without previous MI, 3.4% of patients in the placebo group died vs 2.9% in the alirocumab group (aHR 0.87; 95% CI, 0.72-1.05;  $P_{\text{interaction}} = 0.81$ ). Likewise, estimated absolute risk reduction for death was numerically greater in patients with vs without previous MI (1.35%; 95% CI, -0.28 to 2.97% vs 0.41%; 95% CI, -0.14 to 0.97; quantitative  $P_{\text{heterogeneity}} = 0.29$ ). The unadjusted risks of outcomes are shown in Supplemental Fig. S1. Cumulative incidence curves are shown in Figure 2.

### Effect of alirocumab on outcomes stratified by timing of previous MI

In patients with previous MI, the median time from the last MI to the index ACS was 4.5 years. The effect of alirocumab vs placebo on MACE in patients with MI that occurred  $\leq 2$  years before the qualifying ACS (20.5% vs 19.9%; HR, 1.02; 95% CI, 0.78-1.34) did not differ from that in patients with MI that occurred  $> 2$  years before the qualifying ACS (17.8% vs 20.9%; HR, 0.85; 95% CI, 0.71-1.03;  $P_{\text{interaction}} = 0.16$ ) (Fig. 3).

### Safety outcomes

Adverse events and laboratory abnormalities were, in general, similar for alirocumab vs placebo when stratified by previous MI status at baseline (Supplemental Table S3).

### Discussion

Among patients with recent ACS who did not receive alirocumab, those with vs without previous MI had higher risks of MACE and all-cause death. Alirocumab was associated with consistent relative risk reductions in both patients with and without previous MI, with numerically greater absolute benefit in patients with previous MI.

On the basis of multiple major atherosclerotic cardiovascular disease events, the subgroup with previous MI would be classified as very high risk according to the US guidelines.<sup>10</sup> Approximately 18% to 22% of patients with ACS have histories of previous MI.<sup>1-3,7</sup> Indeed, the adjusted risks for MACE and all-cause death were higher for patients with vs without previous MI. The management of patients with recurrent ACS presents a particular challenge for clinicians. Alirocumab reduced risk of MACE and all-cause death in

**Table 2. Event rates and HR of outcomes stratified by MI status at baseline: placebo arm**

	Previous MI n (%)	No previous MI n (%)	Unadjusted HR (95% CI)	P value	Adjusted HR (95% CI)	P value
Primary composite outcome*	378 (20.5)	674 (8.9)	2.41 (2.12-2.73)	< 0.001	1.85 (1.62-2.11)	< 0.001
Any coronary heart disease event <sup>†</sup>	440 (23.9)	909 (11.9)	2.08 (1.86-2.34)	< 0.001	1.67 (1.48-1.88)	< 0.001
Major coronary heart disease event <sup>‡</sup>	336 (18.2)	563 (7.4)	2.56 (2.23-2.93)	< 0.001	1.97 (1.71-2.28)	< 0.001
Any cardiovascular event <sup>§</sup>	477 (25.9)	997 (13.1)	2.07 (1.85-2.30)	< 0.001	1.63 (1.45-1.83)	< 0.001
Composite of death from any cause, nonfatal MI, or nonfatal ischemic stroke	398 (21.6)	728 (9.6)	2.35 (2.08-2.66)	< 0.001	1.81 (1.59-2.06)	< 0.001
Death from coronary heart disease	87 (4.7)	135 (1.8)	2.62 (2.00-3.43)	< 0.001	1.87 (1.40-2.50)	< 0.001
Death from cardiovascular causes	102 (5.5)	169 (2.2)	2.45 (1.92-3.13)	< 0.001	1.70 (1.31-2.21)	< 0.001
Death from any cause	136 (7.4)	256 (3.4)	2.15 (1.75-2.65)	< 0.001	1.56 (1.25-1.95)	< 0.001
Nonfatal MI	273 (14.8)	449 (5.9)	2.61 (2.24-3.03)	< 0.001	2.03 (1.73-2.38)	< 0.001
Fatal or nonfatal ischemic stroke	50 (2.7)	102 (1.3)	2.01 (1.44-2.83)	< 0.001	1.33 (0.92-1.92)	0.13
Unstable angina requiring hospitalization	20 (1.1)	40 (0.5)	2.05 (1.20-3.51)	0.009	1.73 (0.99-3.04)	0.06
Ischemia-driven coronary revascularization procedure	260 (14.1)	568 (7.5)	1.93 (1.67-2.24)	< 0.001	1.62 (1.38-1.90)	< 0.001
Hospitalization for congestive heart failure	73 (4.9)	106 (1.4)	2.85 (2.11-3.83)	< 0.001	1.66 (1.21-2.28)	0.002


CI, confidence interval; HR, hazard ratio; MI, myocardial infarction.

\* Death from coronary heart disease, nonfatal MI, fatal or nonfatal ischemic stroke, or unstable angina requiring revascularization.

<sup>†</sup> Death from coronary heart disease, nonfatal MI, unstable angina requiring hospitalization, or ischemia-driven coronary revascularization.

<sup>‡</sup> Death from coronary heart disease or nonfatal MI.

<sup>§</sup> Death from cardiovascular cause, nonfatal MI, unstable angina requiring hospitalization, ischemia-driven coronary revascularization procedure, or nonfatal ischemic stroke.



**Figure 1.** Outcomes for allirocumab vs placebo stratified by previous myocardial infarction (MI) status. \*Adjusted for the following independent variables: age ( $\geq 65$  vs  $< 65$  years), sex, race, diabetes mellitus, geographic region, history of heart failure, baseline low-density lipoprotein-cholesterol (LDL-C), lipoprotein(a), intensive statin use, systolic blood pressure at baseline, smoking status, history of ischemic stroke, and history of peripheral artery disease. CI, confidence interval; HR, hazard ratio.


patients receiving maximum tolerated (including  $\sim 90\%$  high-intensity) statins with a numerally greater absolute effect in patients with previous MIs, supporting recent guideline recommendations.<sup>10-12</sup> The lack of statistical significance of allirocumab on MACE and all-cause death in the subgroup of patients with previous MI is most likely due to a relative small number of patients with previous MI.

A previous analysis of the **Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk (FOURIER)** trial in patients with stable atherosclerotic cardiovascular disease and previous MI found that treatment with the PCSK9 inhibitor evolocumab was effective in reducing MACE in those with recent MI ( $< 2$  years) but not in those with only remote MI ( $\geq 2$  years).<sup>13</sup> In the current analysis, the efficacy of allirocumab in patients with ACS was consistent with or without previous MI and in those with previous MI irrespective of whether it had occurred  $\leq 2$  or  $> 2$  years before the qualifying ACS. Therefore, it may be reasonable to consider PCSK9 inhibitor treatment in all patients with ACS and dyslipidemia uncontrolled by statins.

This analysis from the ODYSSEY OUTCOMES trial indicates that previous MI is a marker of higher risk of MACE and death following ACS and, accordingly, that such patients might derive a larger absolute benefit from allirocumab treatment. Previously, effects of allirocumab in patients at very high-risk vs not, according to the US guidelines,<sup>10</sup> have been reported in the ODYSSEY OUTCOMES trial, showing similar findings that patients at very high risk derived a larger absolute benefit from treatment with allirocumab.<sup>14</sup> Similarly,

analyses from this trial have identified several subgroups of post-ACS patients at high risk for recurrent cardiovascular events who derive a greater absolute benefit from allirocumab treatment, including those with type 2 diabetes,<sup>15</sup> polyvascular disease,<sup>16</sup> previous coronary artery bypass graft surgery,<sup>17</sup> higher lipoprotein(a) concentration,<sup>18</sup> and high genome-wide polygenic risk scores.<sup>19</sup> Although the primary analysis of the current study did not reach statistical significance, the numerically greater benefits in patients with previous MI might suggest a true effect if the sample size could be enlarged.

The effects of allirocumab on MACE in patients with previous MI seemed to occur earlier, with the MACE curves separated at approximately 1 year after randomization compared with approximately 2 years for patients without previous MI. Similar findings have also been observed in the FOURIER trial in which the MACE curves separated at approximately 180 days in patients with recent MI ( $\leq 12$  months), compared with approximately 540 days in patients with remote MI ( $> 12$  months).<sup>20</sup> Although we did not collect systematic angiographic information at baseline, it is likely that patients who have had  $> 1$  ACS event have a greater burden of coronary atherosclerosis. More pronounced atherosclerotic lesions are susceptible to be modified by LDL-C lowering. Therefore, intensive LDL-C lowering with allirocumab has a favourable effect on plaque stabilization.<sup>21</sup> More recently, the addition of subcutaneous biweekly allirocumab, compared with placebo, to high-intensity statin therapy in patients with acute MI resulted in significantly



**Figure 2.** Cumulative incidence for alirocumab vs placebo stratified by previous myocardial infarction (MI). **(A)** Major adverse cardiovascular event (MACE) (composite of death from coronary heart disease, nonfatal MI, fatal or nonfatal ischemic stroke, or unstable angina requiring hospitalization). **(B)** All-cause death. CI, confidence interval; HR, hazard ratio; LDL-C, low-density lipoprotein-cholesterol.

greater coronary plaque regression in noninfarct-related arteries after 52 weeks.<sup>22</sup> Whether earlier initiation of treatment (ie, before hospital discharge after ACS) would magnify an early treatment benefit is a hypothesis worthy of testing prospectively.

**Limitations**

First, analyses in subgroups are limited by sample size and power, and the confidence interval of the relative risk reduction in patients with previous MI crossed the line of unity. Second, number of MIs was not recorded, and details on previous MI were based on medical history rather than systematic review of laboratory data and electrocardiographic tracings. Third, we did not investigate the impact of previous atherosclerotic cardiovascular disease events other than MI, such as stroke or peripheral artery disease events, on the clinical efficacy of alirocumab.

**Conclusions**

Patients with recent ACS and previous MI were at higher risk for MACE and death than those without previous MI. Alirocumab reduced the relative risks of these events consistently in patients with or without previous MI but with numerically greater absolute benefit in the former subgroup.

**Acknowledgements**

The authors thank the patients, study coordinators and investigators who participated in this trial. Sophie Rushton-


Smith (MedLink Healthcare Communications, London) provided editorial assistance in the preparation of the manuscript (limited to editing for style, referencing, and figure and table editing) and was funded by Sanofi.

**Funding Sources**

The trial was funded by Sanofi and Regeneron Pharmaceuticals, Inc. The sponsors participated in the selection of the trial sites, the monitoring of the trial, and the supervision of data collection.

**Disclosures**

Dr Chiang has received honoraria from Sanofi, Pfizer, Novartis, Merck Sharp Dohme, AstraZeneca, Daiichi Sankyo, Bayer, and Boehringer Ingelheim. Dr Schwartz has received grants to his institution (University of Colorado) from Sanofi, AstraZeneca, Resverlogix, Roche, and The Medicines Company. Dr Elbez has received research grants from Sanofi and Bristol-Myers Squibb. Dr Szarek has received grants from Sanofi and Regeneron Pharmaceuticals; personal fees from CiVi and Esperion; and grants from Lexicon, Resverlogix, Baxter, and Janssen. Dr Bhatt has served on advisory boards for Cardax, CellProthera, Cereno Scientific, Elsevier Practice Update Cardiology, Janssen, Level Ex, Medscape Cardiology, MyoKardia, Novo Nordisk, PhaseBio, PLx Pharma, and Regado Biosciences and has served on the board of directors for Boston VA Research Institute, Society of Cardiovascular Patient Care, and TobeSoft. He has received research funding



**Figure 3.** Adjusted risk of major adverse cardiovascular event (MACE) stratified by timing of previous myocardial infarction (MI). \*Adjusted for the following independent variables: age ( $\geq 65$  vs  $< 65$  years), sex, race, diabetes mellitus, geographic region, history of heart failure, baseline LDL-C, lipoprotein(a), intensive statin use, systolic blood pressure at baseline, smoking, history of ischemic stroke, and history of peripheral artery disease. CI, confidence interval; HR, hazard ratio; LDL-C, low-density lipoprotein-cholesterol.

from Abbott, Afimmune, Amarin, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Cardax, Chiesi, CSL Behring, Eisai, Ethicon, Ferring Pharmaceuticals, Forest Laboratories, Fractyl, HLS Therapeutics, Idorsia, Ironwood, Ischemix, Janssen, Lexicon, Lilly, Medtronic, MyoKardia, Novo Nordisk, Owkin, Pfizer, PhaseBio, PLx Pharma, Regeneron, Roche, Sanofi, Synaptic, and The Medicines Company and has received royalties from Elsevier (Editor, *Cardiovascular Intervention: A Companion to Braunwald's Heart Disease*); served as site co-investigator for Abbott, Biotronik, Boston Scientific, CSI, St. Jude Medical (now Abbott), and Svelte and has served as Trustee for American College of Cardiology and has participated in unfunded research for FlowCo, Merck, and Takeda. Dr Bittner has received grant support from Sanofi, Astra Zeneca, DalCor, Esperion, Bayer, The Medicines Company, and Amgen, all paid direct to her institution, and she has received personal fees from Sanofi. Dr Diaz has received research grants from Sanofi, DalCor Pharmaceuticals, Population Health Research Institute, Duke Clinical Research Institute, the TIMI group, Amgen, Cirius, Montreal Health Innovations Coordinating Center, and Lepetit and personal fees as a member of the Executive Steering Committee from Amgen and Cirius. Dr Goodman has received research grants from Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, CSL Behring, Eli Lilly, Merck, Novartis, Pfizer, Regeneron, and Sanofi; honoraria from Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, CSL Behring, Daiichi-Sankyo/American Regent, Eli Lilly, Esperion, Ferring Pharmaceuticals, GlaxoSmithKline, HLS Therapeutics, Janssen/Johnson & Johnson, Merck, Novartis, Novo Nordisk A/C, Pendopharm, Pfizer, Regeneron, Sanofi, Servier, and Valeo Pharma and has served as a consultant or on advisory boards (or both) for Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, CSL Behring, Eli Lilly, Ferring Pharmaceuticals, HLS Therapeutics, Janssen/Johnson & Johnson, Merck, Novartis, Pendopharm, Pfizer,

Regeneron, Sanofi, and Servier. He has received salary support/honoraria from the Heart and Stroke Foundation of Ontario/University of Toronto (Polo) Chair, Canadian Heart Research Centre and MD Primer, Canadian VIGOUR Centre, Cleveland Clinic Coordinating Centre for Clinical Research, Duke Clinical Research Institute, New York University Clinical Coordinating Center, and PERFUSE Research Institute. Dr Hagström has received research grants from the Swedish Heart and Lung Foundation, Sweden; Uppsala University, Sweden; EMPIR European Union Horizon 2020; research support from Amgen and Sanofi and has served as a consultant or on advisory for Amgen, Sanofi, Bayer, Novo-Nordisk, and Boehringer Ingelheim. Dr Harrington has received research grants (all DSMB related) from AstraZeneca, Janssen, and Bristol-Myers Squibb; served on advisory boards for Gilead (uncompensated) and WebMD; and has served on the boards of directors (unpaid) for the American Heart Association and Stanford HealthCare. Dr Jukema has received research grants from the Netherlands Heart Foundation, the Interuniversity Cardiology Institute of the Netherlands, and the European Commission Seventh Framework Programme and research support from Amgen, Astellas, AstraZeneca, Daiichi-Sankyo, Lilly, Merck-Schering-Plough, Pfizer, Roche, and Sanofi. Dr Liberopoulos has received personal fees from Amgen and Sanofi and grants, personal fees, and nonfinancial support from AstraZeneca. He has received personal fees from Novo Nordisk, MSD, Lilly, Servier, Boehringer-Ingelheim, and Novartis and personal fees and nonfinancial support from Bayer and Viatrix. Ms Loy is an employee of Sanofi and may hold shares and/or stock options in the company. Dr Pordy is an employee of Regeneron Pharmaceuticals. Dr White has received grant support paid to the institution and fees from Sanofi-Aventis and Regeneron Pharmaceuticals, Eli Lilly, Omthera Pharmaceuticals, Pfizer USA, Eisai Inc, DalCor Pharma UK Inc, Sanofi-Aventis Australia Pty Ltd, and Esperion Therapeutics Inc. Dr White was on the advisory boards for Genentech, Inc. (an affiliate of



F. Hoffmann-La Roche Ltd, “Roche,” Lytics Post-PCI Advisory Board at European Society of Cardiology) and has received lecture fees from AstraZeneca. Dr Zeiher has been a scientific advisor for Sanofi, Amgen, Pfizer, and Boehringer and speaker for Bayer, Novartis, and Vifor. Dr Simon has received grants from Programme de Recherche Medico Economique and from Instituto de Salud Carlos III, Grant number PI15/01543; personal fees from Astra Zeneca, Novartis, Sanofi, Astellas, and MSD; and grants from Astra Zeneca, Bayer, Boehringer, Daiichi-Sankyo, Eli Lilly, GSK, Novartis, and Sanofi. Dr Steg has received grants and personal fees from Sanofi and Regeneron Pharmaceuticals (as co-chair of the ODYSSEY OUTCOMES trial); grants and personal fees from Amarin (executive steering committee REDUCE IT, consulting, speaking), Bayer (speaking), Servier (Chair CLARIFY registry, DMC); personal fees from Amgen, Bristol Myers Squibb (Steering Committee NAXOS and PAROS studies, speaking), Boehringer Ingelheim (executive steering committee, REDUAL PCI trial), Idorsia (Steering Committee SOS AMI trial), Novartis (consulting, executive steering committee PARADISE MI trial, speaking), Novo Nordisk (consulting, speaking), Pfizer (Critical Event Committee), Sanofi/Lexicon (executive steering committee, SCORED and SOLOIST trials), and Myokardia; personal fees and non-financial support from AstraZeneca (co-chair THEMIS trial; consulting, speaking); in addition, Dr Steg has a patent assigned to Sanofi issued. Dr Erglis has no conflicts of interest to disclose. For detailed author disclosure please see the Declaration of Interest Form ([Supplemental Appendix S2](#)).

## References

1. Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. *N Engl J Med* 2004;350:1495-504.
2. Cannon CP, Blazing MA, Giugliano RP, et al. Ezetimibe added to statin therapy after acute coronary syndromes. *N Engl J Med* 2015;372:2387-97.
3. Pfeffer MA, Claggett B, Diaz R, et al. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. *N Engl J Med* 2015;373:2247-57.
4. Bhatt DL, Eagle KA, Ohman EM, et al. Comparative determinants of 4-year cardiovascular event rates in stable outpatients at risk of or with atherothrombosis. *JAMA* 2010;304:1350-7.
5. Bonaca MP, Storey RF, Theroux P, et al. Efficacy and safety of ticagrelor over time in patients with prior MI in PEGASUS-TIMI 54. *J Am Coll Cardiol* 2017;70:1368-75.
6. Stone GW, Maehara A, Lansky AJ, et al. A prospective natural-history study of coronary atherosclerosis. *N Engl J Med* 2011;364:226-35.
7. Schwartz GG, Steg PG, Szarek M, et al. Alirocumab and cardiovascular outcomes after acute coronary syndrome. *N Engl J Med* 2018;379:2097-107.
8. Schwartz GG, Bessac L, Berdan LG, et al. Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: Rationale and design of the ODYSSEY Outcomes trial. *Am Heart J* 2014;168:682-689.e681.
9. Gail M, Simon R. Testing for qualitative interactions between treatment effects and patient subsets. *Biometrics* 1985;41:361-72.
10. Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. *Circulation* 2019;139:e1082-143.
11. Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: the task force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS). *Eur Heart J* 2019;41:111-88.
12. Pearson GJ, Thanassoulis G, Anderson TJ, et al. 2021 Canadian Cardiovascular Society Guidelines for the management of dyslipidemia for the prevention of cardiovascular disease in adults. *Can J Cardiol* 2021;37:1129-50.
13. Sabatine MS, De Ferrari GM, Giugliano RP, et al. Clinical benefit of evolocumab by severity and extent of coronary artery disease: analysis from FOURIER. *Circulation* 2018;138:756-66.
14. Roe MT, Li QH, Bhatt DL, et al. Risk categorization using new American College of Cardiology/American Heart Association guidelines for cholesterol management and its relation to alirocumab treatment following acute coronary syndromes. *Circulation* 2019;140:1578-89.
15. Ray KK, Colhoun HM, Szarek M, et al. Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial. *Lancet Diabetes Endocrinol* 2019;7:618-28.
16. Jukema JW, Szarek M, Zijlstra LE, et al. Alirocumab in patients with polyvascular disease and recent acute coronary syndrome: ODYSSEY OUTCOMES trial. *J Am Coll Cardiol* 2019;74:1167-76.
17. Goodman SG, Aylward PE, Szarek M, et al. Effects of alirocumab on cardiovascular events after coronary bypass surgery. *J Am Coll Cardiol* 2019;74:1177-86.
18. Bittner VA, Szarek M, Aylward PE, et al. Effect of alirocumab on lipoprotein(a) and cardiovascular risk after acute coronary syndrome. *J Am Coll Cardiol* 2020;75:133-44.
19. Damask A, Steg PG, Schwartz GG, et al. Patients with high genome-wide polygenic risk scores for coronary artery disease may receive greater clinical benefit from alirocumab treatment in the ODYSSEY OUTCOMES trial. *Circulation* 2020;141:624-36.
20. Gencer B, Mach F, Murphy SA, et al. Efficacy of evolocumab on cardiovascular outcomes in patients with recent myocardial infarction: a prespecified secondary analysis from the FOURIER trial. *JAMA Cardiol* 2020;5:1-6.
21. Sugizaki Y, Otake H, Kawamori H, et al. Adding alirocumab to rosuvastatin helps reduce the vulnerability of thin-cap fibroatheroma: an ALTAIR trial report. *JACC Cardiovasc Imaging* 2020;13:1452-4.
22. Räber L, Ueki Y, Otsuka T, et al. Effect of alirocumab added to high-intensity statin therapy on coronary atherosclerosis in patients with acute myocardial infarction: the PACMAN-AMI randomized clinical trial. *JAMA* 2022;327:1771-81.

## Supplementary Material

To access the supplementary material accompanying this article, visit the online version of the *Canadian Journal of Cardiology* at [www.onlinecjc.ca](http://www.onlinecjc.ca) and at <https://doi.org/10.1016/j.cjca.2022.05.021>.